This round, co-led by Medtronic and Johnson and Johnson Development Corporation, also includes Oakwood Medical, Palisades Capital and Accelerated Technology Partners. Existing investors Forbion, Giza, Oxford Biosciences and Triathlon Medical Venture Partners also participated in the round.
John MacMahon, president & CEO of Mitralign, said: “This financing will allow us to advance our endeavor to emulate surgical precision with a catheter-based approach for mitral valve repair.”